In March 2021, our experienced intellectual property, antitrust, and health care litigation lawyers shared some predictions on antitrust policy and enforcement in the health care sector. In “Health Care Antitrust under...more
10/22/2021
/ Antitrust Provisions ,
Biden Administration ,
Competition ,
Drug Pricing ,
Enforcement ,
Executive Orders ,
Federal Trade Commission (FTC) ,
Generic Drugs ,
Health Care Providers ,
Hospitals ,
Legislative Agendas ,
Mergers ,
Patents ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Physicians ,
Prescription Drugs ,
Presidential Appointments ,
Regulatory Agenda ,
Relief Measures ,
Rulemaking Process ,
Section 2 ,
Sherman Act ,
Webinars
After a turbulent year that roiled the economy, and the health care sector more than most, the Democrats emerged with control of both the White House and Congress for the first time since 2014. Business leaders and in-house...more
2/17/2021
/ Abuse of Dominance ,
Antitrust Division ,
Antitrust Immunity ,
Antitrust Litigation ,
Antitrust Provisions ,
Biden Administration ,
Biosimilars ,
CREATE Act ,
Department of Justice (DOJ) ,
Discovery Costs ,
Enforcement ,
Federal Trade Commission (FTC) ,
Generic Drugs ,
Hatch-Waxman ,
Health Care Providers ,
Health Insurance ,
Hospital Mergers ,
Hospitals ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
McCarran-Ferguson Act ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Physicians ,
Prescription Drugs ,
Presidential Appointments ,
Repeal ,
Research and Development ,
Reverse Payments ,
Risk Mitigation ,
Webinars
Tuesday, July 17, 2018, 11:00 A.M. CST -- Proving damages in patent pharmaceutical cases can be challenging, as the Georgia Pacific elements are not clearly adapted for pharma markets. Learn from two experienced practitioners...more
One of the most significant obstacles to drug competition is a patent listed in FDA’s “Orange Book.” The mere listing of a patent can delay competition for months, or even years, and drive up expense for competitors....more
Wednesday, January 17, 2018, 11:00 A.M. CST -- The FDA considers a product a drug-device if it includes at least two of the following: a drug component, device component, or a biologic component. The FDA does not classify as...more
Wednesday, April 19, 2017, 1:00 P.M. CST -- Are you an investor or entrepreneur considering 505(b)(2) drug applications? Join Jake Holdreith, Robins Kaplan, and Ken Phelps, Camargo Pharmaceutical Services for a complimentary...more
Recent changes in patent law that make business method and software patents more difficult to obtain and assert suggest diversifying intellectual property protection strategies that rely on these types of patents. If the...more
There has been a notable uptick in the number and size of jury verdicts related to trade secrets. Over the past year, four of the top ten intellectual property verdicts have been related to claims of trade secret...more
As businesses become more global, and employees more mobile, companies are increasingly realizing that their trade secrets are more at risk. Traditionally, companies would be faced with having to file state law actions on...more
One of the greatest fears of a life sciences company is the possibility of being sued for intellectual property violation shortly before their IPO. Such a lawsuit can destabilize market confidence in the company, raise...more